Holen Sie sich die Stockscreener-App
24.26
0.48%
0.2457
Schlusskurs vom Vortag:
$24.01
Offen:
$24.09
24-Stunden-Volumen:
2.05M
Relative Volume:
0.06
Marktkapitalisierung:
$5.60B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
46.46
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
-3.69%
1M Leistung:
-16.84%
6M Leistung:
-30.50%
1J Leistung:
-54.92%
1-Tages-Spanne:
$23.99
$24.52
1-Wochen-Bereich:
$21.53
$24.52
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
24.18 | 5.56B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.355 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.42 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
82.17 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
567.52 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Truist raises Hims and Hers stock price target on GLP-1 insights - Investing.com Canada
Hims & Hers Health, Inc. Announces Issuance of 0.00% Convertible Senior Notes Due 2032 and Indenture with U.S. Bank Trust Company - Minichart
HIMS stock extends 3-day rally: Hims & Hers targets GLP-1 gold rush in Canada after Novo Nordisk patent expiry - MSN
HIMS Stock Extends 3-Day Rally: Hims & Hers Targets GLP-1 Gold Rush In Canada After Novo Nordisk Patent Expiry - Yahoo Finance
Hims & Hers Health Inc (HIMS) Stock Up 4.2% and Still Undervalued -- GF Score: 77/100 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Hims & Hers H - The National Law Review
Hims & Hers Health issues $402.5 million in convertible senior notes due 2032 - Investing.com
Hims & Hers Health Raises $402.5 Million Via 0% Convertible Notes; Adds Capped Calls at $50.15 Cap - TradingView
Hims & Hers (NYSE: HIMS) issues $402.5M 2032 zero-coupon convertibles - Stock Titan
Hims & Hers stock gains on Canada GLP-1 launch By Investing.com - Investing.com Nigeria
Hims & Hers stock gains on Canada GLP-1 launch - Investing.com Canada
Canadians can now get digital prescriptions for 'generic Ozempic' - Financial Post
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry - Reuters
The Silver Lining of Last Week's Hims & Hers Earnings Miss - MarketBeat
Is Hims and Hers Health Stock a Buy After Its Latest Dip? - AOL.com
HIMS Launches Generic Semaglutide in Canada - GuruFocus
Hims & Hers launches generics for Novo’s semaglutide in Canada - Seeking Alpha
Hers Expands GLP-1 Offering in Canada with Generic Semaglutide - HIMS Investor Relations
Hims & Hers Introduces Access to Generic Semaglutide for Canadian Customers - Hims & Hers Newsroom
Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada - Business Wire
Hims & Hers Health Q1 2026: Strategic Shift to Branded Medications Weighs on Results - IndexBox
Eucalyptus acquisition prospect lifts Hims & Hers Health stock 2.67% higher - Traders Union
HIMS Becomes a Retail Sentiment Standout as Bullish Mentions Rise to 70% - openPR.com
Live Longer and Better. Does Medicine’s New Obsession Really Work? - Barron's
Hims & Hers Health, Inc. - dailyvoice.com
HIMS stock slips overnight: Hims & Hers bulks up debt raise to $350M for Eucalyptus buyout, AI push - MSN
Hims & Hers stock slips as dilution fears outweigh new capital - MSN
Hims & Hers Stock Slips As Dilution Fears Outweigh New Capital - Benzinga
Hims & Hers: Wegovy Deal Fuels Growth (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health Swings to First-Quarter Loss as Weight-Loss Pivot Drives Up Costs - WSJ
Barclays Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $29 - Moomoo
5 Revealing Analyst Questions From Hims & Hers Health’s Q1 Earnings Call - Yahoo Finance
Hims & Hers Health, Inc.: Shareholders Board Members Managers and Company Profile | AR0162508391 - marketscreener.com
Spotting Winners: Hims & Hers Health (NYSE:HIMS) And Healthcare Technology Stocks In Q1 - Yahoo Finance
Hims & Hers (HIMS) CFO sells 7,950 shares after option exercise - Stock Titan
HIMS Maintained by B of A Securities -- Price Target Lowered to $28 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Hims & Hers Health Options Spot-On: On May 19th, 113.05K Contracts Were Traded, With 982.6K Open Interest - Moomoo
Why is Hims & Hers stock being hammered today? By Investing.com - Investing.com Nigeria
Is CAH Becoming the Backbone of US Healthcare Infrastructure? - TradingView
Hims & Hers Massive Stock Drop Explained - The Motley Fool
Hims & Hers Health (HIMS) Is Down 23.5% After Zero-Coupon Convertible Note OfferingWhat's Changed - simplywall.st
Hims & Hers Prices Upsized $350 Million Convertible Notes Offering - TradingView
Hims & Hers Prices Upsized $350 Million Convertible Notes Offeri - GuruFocus
Hims & Hers Stock Stabilizes After Upsized $350 Million Convertible Note Offering - Benzinga
Hims & Hers Plans $300M Convertible Notes for Expansion - TipRanks
Hims prices $350M 0.00% convertible notes due 2032, upsized from $300M - TradingView
Hims & Hers (NYSE: HIMS) sells $350M zero-coupon convertible notes for expansion - Stock Titan
Hims & Hers Health stock price forecast: $21.00 support as HIMS falls 11.02% to $22.29 - Traders Union
HIMS Stock Price, Quote & Chart | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment - 01net
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.19%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):